Novo Continues Two-Day Plunge As CFO Acknowledges 'Extraordinary' Challenges In 2026

Core Insights - Novo Nordisk's stock has experienced a significant decline due to the company's forecast of a sales and operating profit decrease of 5% to 13% for the year [1] Group 1: Company Performance - The decline in sales and operating profit is occurring despite the launch of an oral version of the popular weight-loss drug Wegovy [1] - Pricing pressures are anticipated following a Most Favored Nation deal, which may further impact the company's financial performance [1] Group 2: Market Context - The launch of the oral Wegovy pill is seen as a critical move for Novo Nordisk, but the market dynamics, including competition and regulatory challenges, could pose additional hurdles [1]